Ublituximab Phase II Success

A board to discuss future MS therapies in early stage (Phase I or II) trials.
Post Reply
User avatar
NHE
Volunteer Moderator
Posts: 5285
Joined: Sat Nov 20, 2004 3:00 pm
Contact:

Ublituximab Phase II Success

Post by NHE » Thu Mar 07, 2019 5:10 pm

Ublituximab targets CD20 and depletes B cells. Researchers report that their phase II study was successful.

https://multiplesclerosisnewstoday.com/ ... cal-trial/

User avatar
NHE
Volunteer Moderator
Posts: 5285
Joined: Sat Nov 20, 2004 3:00 pm
Contact:

Re: Ublituximab Phase II Success

Post by NHE » Thu Mar 07, 2019 11:02 pm

http://www.tgtherapeutics.com/pipeline/TGTX-1101.cfm
Ublituximab (TG-1101) is a monoclonal antibody that targets a unique epitope on the B-lymphocyte CD20 antigen. Ublituximab (TG-1101) has been bioengineered to deliver enhanced clinical activity and potency. Developed for the treatment of B-cell proliferative disorders, including Non-Hodgkin's Lymphoma ("NHL") and Chronic Lymphocytic Leukemia ("CLL"), anti-CD20 antibodies target and aid in the depletion of B-lymphocytes. Anti-CD20 antibodies have also been shown to be effective in treating select autoimmune diseases such as Rheumatoid Arthritis ("RA") and Systemic Lupus Erythematosus ("SLE"), along with the neurological disorder Multiple Sclerosis ("MS"). Ublituximab is currently in Phase 3 clinical development for patients with hematologic malignancies and patients with multiple sclerosis.
Ublituximab Publications: http://www.tgtherapeutics.com/publications.cfm

User avatar
zen2010
Family Elder
Posts: 217
Joined: Mon Mar 15, 2010 3:00 pm
Location: Villeurbanne, France

Re: Ublituximab Phase II Success

Post by zen2010 » Fri Mar 08, 2019 1:17 am

Thks for the info.

It looks like Rituxan or Ocrevus (Anti- CD20 antibodies).
It's for both RR and PP.

Post Reply
  • Similar Topics
    Replies
    Views
    Last post